Biogen Inc. (IDP.F)
| Previous close | 214.60 |
| Open | 211.80 |
| Bid | 210.40 x 10000 |
| Ask | 214.70 x 10000 |
| Day's range | 211.80 - 211.80 |
| 52-week range | 178.30 - 266.00 |
| Volume | |
| Avg. volume | 28 |
| Market cap | 30.837B |
| Beta (5Y monthly) | -0.02 |
| PE ratio (TTM) | 28.43 |
| EPS (TTM) | 7.45 |
| Earnings date | 23 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 413.19 |
Investor's Business DailyEli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug
Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.
Insider MonkeyBiogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The strategy outperformed the Russell 1000 Value Index in the first quarter. On an absolute basis, the strategy has gained 9 out of eleven sectors it invested in during […]
GlobeNewswireBiogen Completes Acquisition of Human Immunology Biosciences
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). “We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indicat
